TOK-001 (Galeterone) and TAK-700 (Orteronel) were shown in preclinical studies to antagonize the AR and CYP17A1 and decrease the overall expression of AR in PCa cells (90, 91). This evidence concerns the gene CYP17A1 and posterior cortical atrophy.